Basilea Surpasses 2025 Revenue Targets, Eyes Pipeline Growth

Event summary

  • Basilea reported 11% total revenue growth in 2025, reaching CHF 232.4 million, driven by a 15% increase in royalty income from Cresemba.
  • Operating profit decreased to CHF 51.5 million due to a CHF 12 million upfront payment for in-licensing ceftibuten-ledaborbactam, but net cash position tripled to CHF 86.9 million.
  • Phase 3 studies for fosmanogepix are progressing as planned, with data readout expected in early 2028.
  • Basilea expects double-digit revenue and operating profit growth in 2026, with a shift towards higher-margin contract revenue.
  • The company aims to launch two new products by 2030, potentially doubling current in-market sales.

The big picture

Basilea's strong 2025 results underscore its strategic focus on severe bacterial and fungal infections, with Cresemba and Zevtera driving consistent revenue growth. The company's financial strength positions it to advance its pipeline and pursue external opportunities, reflecting broader industry trends toward targeted anti-infective solutions. The upcoming launches of fosmanogepix and ceftibuten-ledaborbactam could further solidify its market position, provided clinical and commercial execution remains on track.

What we're watching

Pipeline Execution
The pace at which fosmanogepix and ceftibuten-ledaborbactam advance through clinical trials will determine Basilea's ability to meet its 2030 growth targets.
Commercial Momentum
Whether Cresemba can maintain its strong sales growth in key markets, particularly the US and Europe, before potential generic competition emerges.
Financial Flexibility
How Basilea balances increased R&D investments with maintaining a strong cash position to seize external growth opportunities.